<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948697</url>
  </required_header>
  <id_info>
    <org_study_id>AdvanTIG-206</org_study_id>
    <nct_id>NCT04948697</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC</brief_title>
  <official_title>A Phase 2, Randomized, Open-labeled Clinical Study Investigating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab Plus BAT1706 and of Tislelizumab Plus BAT1706 as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the&#xD;
      efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and&#xD;
      tislelizumab plus BAT1706, as first-line treatment in participants with advanced HCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) as assessed by the investigator</measure>
    <time_frame>Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as assessed by the investigator</measure>
    <time_frame>time from the first confirmed objective response until the first documentation of disease progression or death, whichever comes first. assessed up to 24 months</time_frame>
    <description>DOR is the time from the date of first documentation of a partial response (PR) or better to the date of first documentation of progressive disease (PR or better). DOR will be assessed based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIme to Response (TTR) as assessed by the investigator</measure>
    <time_frame>time from the date of first dose of study drug to the first documentation of response, assessed up to 24 months</time_frame>
    <description>TTR is defined as the time from the date of first dose administration to the date of first documented partial response (PR) or better by the investigator. TTR will be assessed based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) as assessed by the investigator</measure>
    <time_frame>time from the first confirmed objective response until the first documentation of disease progression or death, whichever comes first, assessed up to 24 months</time_frame>
    <description>DCR is defined as the percentage of participants who achieve complete response (CR), partial response (PR) or durable stable disease (stable disease defined as greater than or equal to (≥) 24 weeks)). The DCR will be assessed based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>time from the first confirmed objective response until the first documentation of disease progression or death, whichever comes first, assessed up to 24 months</time_frame>
    <description>defined as the proportion of participants who achieve complete response (CR), partial response (PR), or durable stable disease (stable disease defined as greater than or equal to (≥) 24 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as assessed by the investigator</measure>
    <time_frame>time from the date of the first dose of study drug to the date of first documentation of disease progression or death, whichever occurs first, assessed up to 24 months</time_frame>
    <description>PFS will be evaluated by the investigator according to RECIST version 1.1. PFS is defined as the time from the date of first dose to the date of first documentation of disease progression or date of death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>time from the date of the first dose of study drug until the date of death from any cause, assessed up to 24 months</time_frame>
    <description>measured time from the date of the first dose of study drug until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs),</measure>
    <time_frame>time from the date of the first dose of study drug until the date of death from any cause, assessed up to 24 months</time_frame>
    <description>severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version [v] 5.0, vital signs and clinical laboratory test results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ociperlimab at specified timepoints</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Collected at time intervals: predose on Day 1 of Cycles 1, 2, 5, 9 and 17. Postdose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of tislelizumab at specified timepoints</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Collected at time intervals: predose on Day 1 of Cycles 1, 2, 5, 9 and 17. Postdose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of BAT1706 at specified timepoints</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>Collected at time intervals: predose on Day 1 of Cycles 1,2, 5, 9, and 17. Postdose on Day 1of Cycles 1 and 5 and EOT Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenic Response to ociperlimab</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>evaluated through detection of antidrug antibodies (ADAs). Time to onset of immunogenic response will be reported Collected at time intervals: predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at Safety Follow-up Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenic Response to tislelizumab</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>evaluated through detection of antidrug antibodies (ADAs). Time to onset of immunogenic response will be reported Collected at time intervals: predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at Safety Follow-up Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenic Response to BAT1706</measure>
    <time_frame>Through study completion, up to 24 months</time_frame>
    <description>evaluated through detection of antidrug antibodies (ADAs). Time to onset of immunogenic response will be reported Collected at time intervals: predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at EOT Visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: ociperlimab + tislelizumab + BAT1706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: tislelizumab + BAT1706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ociperlimab</intervention_name>
    <description>900 mg intravenously once every 3 weeks (dosed in 21-day cycles)</description>
    <arm_group_label>Arm A: ociperlimab + tislelizumab + BAT1706</arm_group_label>
    <other_name>BGB-A1217</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200 mg intravenously once every 3 weeks (dosed in 21-day cycles)</description>
    <arm_group_label>Arm A: ociperlimab + tislelizumab + BAT1706</arm_group_label>
    <arm_group_label>Arm B: tislelizumab + BAT1706</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT1706</intervention_name>
    <description>15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)</description>
    <arm_group_label>Arm A: ociperlimab + tislelizumab + BAT1706</arm_group_label>
    <arm_group_label>Arm B: tislelizumab + BAT1706</arm_group_label>
    <other_name>Bevacizumab Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed HCC&#xD;
&#xD;
          2. BCLC Stage C disease, or BCLC Stage B disease that is not amenable to or has&#xD;
             progressed after loco-regional therapy, and is not amenable to a curative treatment&#xD;
             approach&#xD;
&#xD;
          3. Tumor tissue required for an evaluable PD-L1 expression result&#xD;
&#xD;
          4. No prior systemic therapy for HCC&#xD;
&#xD;
          5. At least 1 measurable lesion as defined per RECIST v1.1&#xD;
&#xD;
          6. Adequate organ function during screening and before randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC&#xD;
             histology&#xD;
&#xD;
          2. Prior therapy with antibody or drug specifically targeting T-cell costimulation or&#xD;
             checkpoint pathway; prior treatment with bevacizumab or its biosimilars&#xD;
&#xD;
          3. Prior history of ≥ Grade 2 hepatic encephalopathy&#xD;
&#xD;
          4. Leptomeningeal disease or uncontrolled, untreated brain metastasis&#xD;
&#xD;
          5. Active autoimmune diseases or history of autoimmune diseases that may relapse&#xD;
&#xD;
          6. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung&#xD;
             diseases including pulmonary fibrosis, acute lung diseases&#xD;
&#xD;
          7. Infection (including tuberculosis) requiring systemic antibacterial, antifungal, or&#xD;
             antiviral therapy within 14 days of randomization&#xD;
&#xD;
          8. Prior allogeneic stem cell transplantation or organ transplantation&#xD;
&#xD;
          9. Significant cardiovascular risk factors&#xD;
&#xD;
         10. Untreated or incompletely treated esophageal or gastric varices with bleeding or high&#xD;
             risk of bleeding&#xD;
&#xD;
         11. History of severe hypersensitivity reactions to other monoclonal antibodies&#xD;
&#xD;
         12. Administered a live vaccine ≤ 28 days before randomization&#xD;
&#xD;
        NOTE: Other protocol Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing University Three Gorges Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mengchao Hepatobiliary Hospital of Fujian Medical University</name>
      <address>
        <city>Gulou</city>
        <state>Fuzhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hwa Mei Hospital, University of Chinese Academy of Sciences</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation (CGMF) - Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

